Experimental COVID-19 vaccine offers long-term protection against severe disease

A newly published follow-up study has found that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, still provide protection against lung disease in rhesus macaques one year after they had been vaccinated as infants.